Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Regulatory News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.50
Bid: 16.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 1.00 (6.25%)
Open: 16.50
High: 16.50
Low: 16.50
Prev. Close: 16.50
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Mar 2023 10:31

RNS Number : 0102S
Destiny Pharma PLC
06 March 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Destiny Pharma Plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Unicorn Asset Management Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

Unicorn AIM VCT plc

City and country of registered office (if applicable)

Newton Abbot, United Kingdom

5. Date on which the threshold was crossed or reachedvi:

01 March 2023

6. Date on which issuer notified (DD/MM/YYYY):

03 March 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

4.65%

4.65%

4,076,923

Position of previous notification (if

applicable)

5.14%

5.14%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary shares

GB00BDHSP575

4,076,923

4.65%

SUBTOTAL 8. A

4,076,923

4.65%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Figures are based on total voting rights of 87,742,819

 

Place of completion

Unicorn Asset Management Limited, Preachers Court, Charterhouse, Charterhouse Square, London, EC1M 6AU

Date of completion

03 March 2023

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAEDKEDEDEFA
Date   Source Headline
9th Sep 20217:00 amRNSInterim results for six months ended 30 June 2021
23rd Aug 20217:00 amRNSNotice of Interim Results
2nd Aug 20217:00 amRNSSecondary endpoint analysis from Phase 2b trial
9th Jul 20218:00 amRNSXF-73 Phase 2b data to be presented at ECCMID
6th Jul 20217:00 amRNSNTCD-M3 RD Agreement with US Dept Veterans Affairs
2nd Jul 20218:00 amRNSScientific Advisor Gerding chairs C Diff symposium
29th Jun 20218:24 amRNSDEST to present at Shares & AJ Bell Webinar 6/7/21
10th Jun 20215:00 pmRNSDirector Dealing
10th Jun 20217:00 amRNSXF-73 data abstract to be presented at 2021 ECCMID
7th Jun 20217:00 amRNSDestiny Pharma welcomes G7’s Communique on AMR
3rd Jun 202112:03 pmRNSResult of AGM
2nd Jun 20217:00 amRNSPositive update on microbiome therapeutic NTCD-M3
25th May 20217:00 amRNSFurther information re AGM
19th May 20217:00 amRNSNotice to Register for 2021 AGM
6th May 202110:00 amRNSConference Attendance for May 2021
4th May 20217:00 amRNSPosting of Annual Report and Notice of AGM
30th Apr 20217:00 amRNSDirector Dealing
23rd Apr 20217:00 amRNSDirector Dealing
15th Apr 20218:00 amRNSFY 2020 Investor Presentation
14th Apr 20217:00 amRNSFinal Results
29th Mar 202112:45 pmRNSExercise of Options and Total Voting Rights
29th Mar 202112:00 pmRNSDestiny Pharma to Join Equity Development Webinar
29th Mar 202111:06 amRNSSecond Price Monitoring Extn
29th Mar 202111:00 amRNSPrice Monitoring Extension
29th Mar 202110:15 amRNSExercise of Options and Total Voting Rights
29th Mar 20219:06 amRNSSecond Price Monitoring Extn
29th Mar 20219:00 amRNSPrice Monitoring Extension
29th Mar 20217:00 amRNSDestiny Pharma Reports Positive Phase 2b Results
16th Mar 20217:00 amRNSNotice of Results
15th Mar 20217:00 amRNSDestiny Pharma Announces Agreement with NIAID
10th Mar 20212:15 pmRNSExercise of Options and Total Voting Rights
10th Mar 20217:00 amRNSDestiny Pharma CSO Joins UKRI COVID-19 Taskforce
10th Feb 20212:05 pmRNSSecond Price Monitoring Extn
10th Feb 20212:00 pmRNSPrice Monitoring Extension
3rd Feb 20217:00 amRNSBrazilian Patent Granted for XF-73 nasal gel
2nd Feb 20217:05 amRNSDestiny Pharma to join panel discussion at LSX
2nd Feb 20217:00 amRNSDestiny Pharma Appoints Professor Mark Wilcox
21st Jan 20214:41 pmRNSSecond Price Monitoring Extn
21st Jan 20214:35 pmRNSPrice Monitoring Extension
21st Jan 20214:31 pmRNSGrant of Share Options
21st Jan 20218:28 amRNSDestiny Pharma Investor Presentation
14th Jan 202111:05 amRNSSecond Price Monitoring Extn
14th Jan 202111:00 amRNSPrice Monitoring Extension
7th Jan 202111:05 amRNSSecond Price Monitoring Extn
7th Jan 202111:00 amRNSPrice Monitoring Extension
7th Jan 20217:00 amRNSDestiny Pharma: Directors Dealings
6th Jan 20218:00 amRNSDestiny Pharma Appoints Stephanie Bewick as CBO
5th Jan 20217:00 amRNSPhase 2b trial of XF-73 completes recruitment
23rd Dec 20202:09 pmRNSGrant of share options
22nd Dec 20207:00 amRNSUpdate on the recently acquired NTCD-M3 programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.